Nuzenio

Level Clinical Trial

Level Clinical Trial news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 6 latest news signals 6 publisher sources 100/100 entity strength

Latest news

Tenax Announces Phase 3 LEVEL Trial Topline Results for TNX-103 in PH-HFpEF - clinicaltrialvanguard.comclinicaltrialvanguard.com · Tue, 11 Aug 2026 06:34:18 GMTTNX-103 Misses Primary Endpoint in Phase 3 LEVEL PH-HFpEF Trial - HCPLiveHCPLive · Mon, 10 Aug 2026 15:03:24 GMTTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF - investingnews.cominvestingnews.com · Mon, 10 Aug 2026 12:54:11 GMTHeart failure drug from Tenax Therapeutics fails in pivotal study - STATSTAT · Mon, 10 Aug 2026 11:43:53 GMTOrion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 11:19:58 GMTTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswireGlobeNewswire · Fri, 31 Jul 2026 11:00:00 GMT

Timeline

Tue, 11 Aug 2026 06:34:18 GMTTenax Announces Phase 3 LEVEL Trial Topline Results for TNX-103 in PH-HFpEF - clinicaltrialvanguard.com
Mon, 10 Aug 2026 15:03:24 GMTTNX-103 Misses Primary Endpoint in Phase 3 LEVEL PH-HFpEF Trial - HCPLive
Mon, 10 Aug 2026 12:54:11 GMTTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF - investingnews.com
Mon, 10 Aug 2026 11:43:53 GMTHeart failure drug from Tenax Therapeutics fails in pivotal study - STAT
Mon, 10 Aug 2026 11:19:58 GMTOrion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint - The Manila Times
Fri, 31 Jul 2026 11:00:00 GMTTenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Level Clinical Trial.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.